Alexander Visekruna

Dr. Alexander Visekruna

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
MLMaik Luu
Maik Luu
ZRZeno Riester
Zeno Riester
ABAdrian Baldrich
Adrian Baldrich
NRNicole Reichardt
Nicole Reichardt
SYSamantha Yuille
Samantha Yuille
AVAlexander Visekruna
Alexander Visekruna
Emerging data demonstrate that the activity of immune cells can be modulated by microbial molecules. Here, we show that the short-chain fatty acids (SCFAs) pentanoate and butyrate enhance the anti-tumor activity of cytotoxic T lymphocytes (CTLs) and chimeric antigen receptor (CAR) T cells through metabolic and epigenetic reprograming. We show that in vitro treatment of CTLs and CAR T cells with pentanoate and butyrate increases the function of mTOR as a central cellular metabolic sensor, and inhibits class I histone deacetylase activity. This reprogramming results in elevated production of effector molecules such as CD25, IFN-γ and TNF-α, and significantly enhances the anti-tumor activity of antigen-specific CTLs and ROR1-targeting CAR T cells in syngeneic murine melanoma and pancreatic cancer models. Our data shed light onto microbial molecules that may be used for enhancing cellular anti-tumor immunity. Collectively, we identify pentanoate and butyrate as two SCFAs with therapeutic utility in the context of cellular cancer immunotherapy.

15 February 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
MLMaik Luu
Maik Luu
SPSabine Pautz
Sabine Pautz
VKVanessa Kohl
Vanessa Kohl
RSRajeev Singh
Rajeev Singh
RRRossana Romero
Rossana Romero
AVAlexander Visekruna
Alexander Visekruna
Short-chain fatty acids (SCFAs) have immunomodulatory effects, but the underlying mechanisms are not well understood. Here we show that pentanoate, a physiologically abundant SCFA, is a potent regulator of immunometabolism. Pentanoate induces IL-10 production in lymphocytes by reprogramming their metabolic activity towards elevated glucose oxidation. Mechanistically, this reprogramming is mediated by supplying additional pentanoate-originated acetyl-CoA for histone acetyltransferases, and by pentanoate-triggered enhancement of mTOR activity. In experimental mouse models of colitis and multiple sclerosis, pentanoate-induced regulatory B cells mediate protection from autoimmune pathology. Additionally, pentanoate shows a potent histone deacetylase-inhibitory activity in CD4+ T cells, thereby reducing their IL-17A production. In germ-free mice mono-colonized with segmented filamentous bacteria (SFB), pentanoate inhibits the generation of small-intestinal Th17 cells and ameliorates SFB-promoted inflammation in the central nervous system. Taken together, by enhancing IL-10 production and suppressing Th17 cells, the SCFA pentanoate might be of therapeutic relevance for inflammatory and autoimmune diseases.

26 September 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MLMaik Luu
Maik Luu
KWKatharina Weigand
Katharina Weigand
FWFatana Wedi
Fatana Wedi
CBCarina Breidenbend
Carina Breidenbend
HLHanna Leister
Hanna Leister
AVAlexander Visekruna
Alexander Visekruna
The gut microbiota produces metabolites such as short-chain fatty acids (SCFAs) that regulate the energy homeostasis and impact on immune cell function of the host. Recently, innovative approaches based on the oral administration of SCFAs have been discussed for therapeutic modification of inflammatory immune responses in autoimmune diseases. So far, most studies have investigated the SCFA-mediated effects on CD4+ T cells and antigen presenting cells. Here we show that butyrate and, to a lesser degree, propionate directly modulate the gene expression of CD8+ cytotoxic T lymphocytes (CTLs) and Tc17 cells. Increased IFN-γ and granzyme B expression by CTLs as well as the molecular switch of Tc17 cells towards the CTL phenotype was mediated by butyrate independently of its interaction with specific SCFA-receptors GPR41 and GPR43. Our results indicate that butyrate strongly inhibited histone-deacetylases (HDACs) in CD8+ T cells thereby affecting the gene expression of effector molecules. Accordingly, the pan-HDAC inhibitors trichostatin A (TSA) and sodium valproate exerted similar influence on CD8+ T cells. Furthermore, higher acetate concentrations were also able to increase IFN-γ production in CD8+ T lymphocytes by modulating cellular metabolism and mTOR activity. These findings might have significant implications in adoptive immunotherapy of cancers and in anti-viral immunity.

31 May 2014 in Archivum Immunologiae et Therapiae Experimentalis
Verified
Journal Article
Open access
PDF file
HMHans-Willi Mittrücker
Hans-Willi Mittrücker
AVAlexander Visekruna
Alexander Visekruna
MHMagdalena Huber
Magdalena Huber
It is well established that CD8+ T cells constitute an important branch of adaptive immunity contributing to clearance of intracellular pathogens and providing long-term protection. These functions are mostly fulfilled by the best characterized subpopulation of CD8+ T cells, the cytotoxic T lymphocytes (also called Tc1 cells), owing to their ability to kill infected cells and to secrete cytokines such as interferon-γ and tumor necrosis factor-α. However, there is growing evidence for alternative CD8+ T cell fates influencing CD4+ T-cell-mediated responses in the context of allergy, autoimmunity and infections. Thus, like subpopulations of CD4+ T cells, also CD8+ T cells under particular conditions acquire the expression of interleukin (IL)-4, IL-5, IL-9, IL-13, IL-17 or suppressive activity and thereby influence immune responses. The process of CD8+ T-cell differentiation is dictated by antigen strength, co-stimulatory molecules and cytokines. These environmental cues induce transcription factors further specifying CD8+ T-cell decision into Tc1, Tc2, Tc9, Tc17 or CD8+ T regulatory fate. Here, we discuss our current understanding about functional diversity of effector CD8+ T cells and contribution of transcription factors to this process.

28 August 2017 in Frontiers in Immunology
Verified
Journal Article
Open access
MKMeike Kespohl
Meike Kespohl
NVNiyati Vachharajani
Niyati Vachharajani
MLMaik Luu
Maik Luu
Hani HarbHani Harb
Hani Harb
SPSabine Pautz
Sabine Pautz
AVAlexander Visekruna
Alexander Visekruna
Short-chain fatty acids (SCFAs), which are generated by the bacterial fermentation of dietary fibers, promote expansion of regulatory T cells (Tregs). Potential therapeutic value of SCFAs has been recently highlighted in the experimental models of T cell-mediated autoimmunity and allergic inflammation. These studies suggest that physiological intestinal concentrations of SCFAs within the millimolar range are crucial for dampening inflammation-mediated processes. Here, we describe opposing effects of SCFAs on T cell-mediated immune responses. In accordance with published data, lower butyrate concentrations facilitated differentiation of Tregs in vitro and in vivo under steady-state conditions. In contrast, higher concentrations of butyrate induced expression of the transcription factor T-bet in all investigated T cell subsets resulting in IFN-g-producing Tregs or conventional T cells. This effect was mediated by the inhibition of histone deacetylase (HDAC) activity and was independent of SCFA-receptors FFA2 and FFA3 as well as of Na+-coupled SCFA transporter Slc5a8. Importantly, while butyrate was not able to induce the generation of Tregs in the absence of TGF-b1, the expression of T-bet and IFN-g was triggered upon stimulation of CD4+ T cells with this SCFA alone. Moreover, the treatment of germ-free (GF) mice with butyrate enhanced the expression of T-bet and IFN-g during acute colitis. Our data reveal that, depending on its concentration and immunological milieu, butyrate may exert either beneficial or detrimental effects on the mucosal immune system.

10 December 2012 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
MHMagdalena Huber
Magdalena Huber
SHSylvia Heink
Sylvia Heink
APAxel Pagenstecher
Axel Pagenstecher
KRKatharina Reinhard
Katharina Reinhard
JRJosephine Ritter
Josephine Ritter
MLMichael Lohoff
Michael Lohoff
IL-17–producing CD8+ T (Tc17) cells are detectible in multiple sclerosis (MS) lesions; however, their contribution to the disease is unknown. To identify functions of Tc17 cells, we induced EAE, a murine model of MS, in mice lacking IFN regulatory factor 4 (IRF4). IRF4-deficient mice failed to generate Tc17 and Th17 cells and were resistant to EAE. After adoptive transfer of WT CD8+ T cells and subsequent immunization for EAE induction in these mice, the CD8+ T cells developed a Tc17 phenotype in the periphery but could not infiltrate the CNS. Similarly, transfer of small numbers of WT CD4+ T cells alone did not evoke EAE, but when transferred together with CD8+ T cells, IL-17–producing CD4+ (Th17) T cells accumulated in the CNS and mice developed severe disease. Th17 accumulation and development of EAE required IL-17A production by CD8+ T cells, suggesting that Tc17 cells are required to promote CD4+ T cell–mediated induction of EAE. Accordingly, patients with early-stage MS harbored a greater number of Tc17 cells in the cerebrospinal fluid than in peripheral blood. Our results reveal that Tc17 cells contribute to the initiation of CNS autoimmunity in mice and humans by supporting Th17 cell pathogenicity.